LifeVantage Revenue Drops 20% as GLP-1 Sales Slump

Event summary

LifeVantage reported a 23.1% revenue decline in Q4 2026, with full-year revenue down 20.1% to $182.6 million.
Americas revenue fell 23.2%, while Asia/Pacific & Europe declined 6.9%.
Active accounts dropped 21.2% year-over-year, with independent consultants down 15.7%.
Adjusted EBITDA fell to $13.7 million from $22.1 million in fiscal 2025.
Company repurchased $2 million in shares, with $58.5 million remaining in its $60 million program.

The big picture

LifeVantage's significant revenue decline reflects broader challenges in the health and wellness sector, particularly with GLP-1 product sales. The company's strategic focus on brand strengthening and operational excellence will be critical as it navigates a competitive direct-sales market. With a debt-free balance sheet and $58.5 million remaining in its share repurchase program, the company has financial flexibility but faces pressure to demonstrate tangible improvements in its core metrics.

What we're watching

Brand Repositioning: Whether LifeVantage can successfully strengthen its brand and consumer proposition amid declining sales.
Operational Excellence: The pace at which the company can drive operational improvements to offset revenue declines.
Market Recovery: How broader macroeconomic conditions will impact the company's ability to rebound in key regions.